PUMA BIOTECHNOLOGY, INC. (PBYI) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $0.00; Long-term Debt, Excluding Current MaturitiesUSD $0.00; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2026-03-31: Long-term Debt, Current MaturitiesUSD $11.28M; Long-term Debt, Excluding Current MaturitiesUSD $0.00; Long-term DebtUSD $11.34M; Long-Term Debt, Maturity, Year OneUSD $11.34M.
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $22.52M; Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD $0.00; Long-term DebtUSD $22.68M; Long-Term Debt, Maturity, Year OneUSD $22.68M.
PUMA BIOTECHNOLOGY, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Notes Payable, Related Parties, Noncurrent USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $0.00 | (m) | (m) | (m) | (m) | $102.00M | $0.00 | (m) | (m) | (m) | (m) |
| 2026-03-31 | $11.28M | $0.00 | $11.34M | $11.34M | (m) | (m) | $102.00M | $59.00K | (m) | (m) | (m) | (m) |
| 2025-12-31 | $22.52M | (m) | (m) | (m) | (m) | (m) | (m) | $152.00K | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $0.00 | $22.68M | $22.68M | (m) | (m) | $102.00M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $33.72M | $0.00 | $34.01M | $22.68M | (m) | $11.33M | $102.00M | $291.00K | (m) | (m) | (m) | (m) |
| 2025-06-30 | $34.00M | $10.87M | $45.34M | $22.68M | (m) | $22.66M | $102.00M | $473.00K | (m) | (m) | (m) | (m) |
| 2025-03-31 | $45.33M | $10.65M | $56.67M | $22.67M | (m) | $34.00M | $102.00M | $696.00K | (m) | (m) | (m) | (m) |
| 2024-12-31 | $45.33M | $21.72M | (m) | (m) | (m) | (m) | (m) | $956.00K | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $68.00M | $45.33M | $22.67M | (m) | $102.00M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $45.33M | $32.75M | $79.33M | $45.33M | $22.67M | $11.33M | $102.00M | $1.26M | (m) | (m) | (m) | (m) |
| 2024-06-30 | $45.33M | $43.73M | $90.67M | $45.33M | $22.67M | $22.66M | $102.00M | $1.60M | (m) | (m) | (m) | (m) |
| 2024-03-31 | $45.33M | $54.69M | $102.00M | $45.33M | $22.67M | $34.00M | $102.00M | $1.98M | (m) | (m) | (m) | (m) |
| 2023-12-31 | $34.00M | $65.66M | (m) | (m) | (m) | (m) | (m) | $2.34M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | $102.00M | $34.00M | $45.33M | (m) | $102.00M | (m) | $22.67M | (m) | (m) | (m) |
| 2023-09-30 | $22.66M | $76.63M | $102.00M | $34.00M | $45.33M | $0.00 | $102.00M | $2.70M | $22.67M | (m) | (m) | (m) |
| 2023-06-30 | $11.33M | $87.62M | $102.00M | $34.00M | $45.33M | $0.00 | $102.00M | $3.05M | $22.67M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $98.62M | $102.00M | (m) | $34.00M | (m) | $102.00M | $3.38M | $45.33M | $22.67M | (m) | (m) |
| 2022-12-31 | $0.00 | $98.31M | (m) | (m) | (m) | (m) | (m) | $3.69M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $102.00M | $0.00 | $34.00M | (m) | $102.00M | (m) | $45.33M | $22.67M | (m) | (m) |
| 2022-09-30 | (m) | $97.99M | $102.00M | $0.00 | $34.00M | $0.00 | $102.00M | $4.01M | $45.33M | $22.67M | (m) | (m) |
| 2022-06-30 | (m) | $97.68M | $102.00M | $0.00 | $34.00M | $0.00 | $102.00M | $4.32M | $45.33M | $22.67M | (m) | (m) |
| 2022-03-31 | (m) | $97.38M | $102.00M | $0.00 | $34.00M | $0.00 | $102.00M | $4.62M | $45.33M | $22.67M | (m) | (m) |
| 2021-12-31 | (m) | $97.09M | (m) | (m) | (m) | (m) | (m) | $4.91M | (m) | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | (m) | $102.00M | $0.00 | $0.00 | (m) | $102.00M | (m) | $34.00M | $45.33M | $22.67M | (m) |
| 2021-09-30 | $0.00 | $96.80M | $102.00M | $0.00 | $0.00 | $0.00 | $102.00M | $5.20M | $34.00M | $45.33M | (m) | (m) |
| 2021-06-30 | $31.43M | $68.71M | $68.71M | (m) | (m) | (m) | $100.00M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $22.86M | $76.35M | $76.35M | (m) | (m) | (m) | $100.00M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $14.29M | $84.03M | (m) | (m) | (m) | (m) | (m) | $5.00M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $84.03M | (m) | (m) | (m) | $100.00M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $5.71M | $91.71M | $91.71M | (m) | (m) | (m) | $100.00M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $96.57M | (m) | (m) | (m) | $100.00M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | $95.75M | (m) | (m) | (m) | $100.00M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $94.96M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $94.96M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $100.00M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | $94.19M | (m) | (m) | (m) | $100.00M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | $93.43M | (m) | (m) | (m) | $100.00M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | $152.84M | (m) | (m) | (m) | $155.00M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | $151.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $155.00M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | $121.05M | (m) | (m) | (m) | $125.00M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $120.27M | (m) | (m) | (m) | $125.00M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $48.56M | (m) | (m) | (m) | $50.00M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $48.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $50.00M | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $150.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |